Trending Now

Nivesh.live

Invest Wisely, Grow Steadily

Menu
Search
Headline
10 reasons why gold is a good buy in 2025 – CNBC TV18
10 reasons why gold is a good buy in 2025 – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday

Tag: Systematix Group

Markets
Sarvesh Gautam

US tariffs on Indian pharma will be hard to implement & inflationary: Systematix’s Vishal Manchanda – CNBC TV18

[ad_1] The United States may find it difficult to impose tariffs on Indian pharmaceutical products as it would likely drive up costs and contribute to inflation, according to Vishal Manchanda, Pharma Analyst at Systematix Group. Manchanda explained that Indian pharma companies operate on lower manufacturing costs compared to the US, and any tariffs would make […]

Back To Top
Translate »